In this paper, we demonstrate the synthesis of the complement component C2 and factors B and D by the human astroglioma cell line U105-MG. All three components were structurally and antigenically similar to their serum counterparts, as determined by biosynthetic labelling studies or Western blot analysis. Northern blot analysis demonstrated that the mRNAs of all three components had the same apparent sizes as the equivalent mRNAs from hepatocyte and monocyte cell lines. Interestingly, U105-MG cells produce two C2 transcripts with sizes of -2.8 and 2.3 kb. Interferon-y (IFN-y) enhanced the expression of C2 and factor B mRNA and protein in a dose-and time-dependent fashion, while factor D expression was refractory to IFN-y. IFN-y appeared to predominantly enhance the expression of the large (2.8 kb) C2 transcript. Kinetic studies demonstrated peak C2 and factor B expression in 48 h in response to IFN-y, similar to the acute-phase response of factor B in serum. These data are the first to demonstrate the synthesis of C2 and factor D by astroglioma cells. Combined with previous reports documenting the synthesis of C3 by astrocytes, our data suggest that endogenous synthesis of complement proteins, and particularly of alternative pathway activation components (C3, factors B and D), may play an important role in host defence in the central nervous system.
INTRODUCTION
Complement proteins C2 and factor B are essential components of the classical and alternative pathways respectively of complement activation. These proteins provide the catalytic subunits of the C3 and C5 convertases of complement. C2 and factor B are structurally similar and their genes are tandemly located on chromosome 6 within the class III region of the major histocompatibility complex (reviewed in [1, 2] ). The expression of these proteins is regulated in a tissue-specific fashion, with synthesis restricted to hepatocytes, monocytes and fibroblasts (reviewed in [3, 4] ). Both molecules are also regulated transcriptionally, with expression being stimulated by lipopolysaccharide (LPS) and cytokines, including interferons, interleukin-I (IL-1) and IL-4 [5] [6] [7] . We have presented evidence that C2 is also regulated at the level of translation [8] .
Factor D is a key enzyme in the alternative pathway of complement activation, cleaving factor B to its proteolytically active state and leading to the formation of the C3 convertase, C3bBb [9] . As with C2 and factor B, factor D expression is also regulated in a tissue-specific fashion, with synthesis restricted primarily to adipocytes [10, 11] , monocytes [12, 13] and the sciatic nerve [11] . Transcriptional regulation of factor D is less well understood. Tumour necrosis factor has been shown to downregulate expression of mouse factor D, also termed adipsin, by adipocytes [14] , and retinoic acid treatment of 3T3-F442A adipocytes down-regulates factor D expression by decreasing the stability of the transcript [15] .
Recent studies have demonstrated that complement proteins are synthesized by astrocytes or astroglioma cell lines [16, 17] . Astrocytes are the major glial cells in the central nervous system (CNS) and function in maintaining a balanced homeostatic environment. There is growing evidence that astrocytes function as immunocompetent cells in the CNS, acting as antigenpresenting cells and responding to and producing several cytokines (for review, see [18] ). Production of complement proteins, and cytokines that regulate complement gene expression, by astrocytes would provide an endogenous source of complement in the CNS. We report here the synthesis of C2 and factors B and D by the astroglioma cell line U105-MG. C2 and factor B synthesis by these cells was upregulated by interferon-y (IFN-y). These results suggest that endogenous complement production in the CNS may be important in host defence in the immunologically privileged CNS.
MATERIALS AND METHODS Cell culture
The astroglioma cell line U105-MG has been described previously [19] . These cells stain positively for glial fibrillary acidic protein, an intracellular protein unique to astrocytes [20] . Cells were maintained in a 50: 50 (v/v) mixture of Dulbecco's modified Eagle's medium and Ham's F-12 (DMEM/F 12; CellGro; Fisher Scientific) supplemented with 10 % heat-inactivated fetal bovine serum (FBS; Hyclone), 2 mM-L-glutamine, 1.5 g of D-glucose/ litre and a mixture of 100 units of penicillin/ml, 100 ,ug of streptomycin/ml and 0.25 ,ug of fungizone/ml (Whittaker Bioproducts Inc. [23] . Samples of RNA (20,ug) were denatured in formaldehyde for 15 with 10 mM-TBS, pH 8.0, containing 0.025 % NaN3, and once with 50 mM-TBS, pH 6.8. The cells were then resuspended in 40 ,u1 of SDS sample buffer, boiled for 3 min, pelleted and the supernatants loaded on 5-20 % gradient polyacrylamide gels in the presence of SDS. Purified factor B (4 jug) was run along with high-and low-molecular-mass standards. After electrophoresis, the gels were stained, destained, dried and exposed to Kodak AR X-Omat film at -90 'C.
Western blot analysis
Aliquots of culture media from U 105-MG cells, controls consisting of freshly prepared culture media, and factor Dcontaining urine from a patient with Fanconi's syndrome [27] were fractionated by electrophoresis on a 5-20 % gel by SDS/PAGE under reducing conditions and transferred to a nitrocellulose filter by electroblotting [28] . The filter was preincubated with 5 % non-fat dried milk in TBS, pH 7.2, to block reactive sites, then incubated with polyclonal antisera to factor D. Protein bands were developed using alkalinephosphatase-conjugated goat anti-rabbit IgG (Bio-Rad).
Statistical analysis
All experiments were performed two to four times, and the data are expressed as the means + S.E.M. P values were calculated by the paired Student's t-test using the StatView 512 + software program. IFN-y We have reported previously that a number of astroglioma cell lines produce variable amounts of C2 and factors B and D [17] . For the present experiments we selected U105-MG cells because they produce substantial amounts of all three proteins. Initial experiments indicated that stimulation with IFN-y increased production of C2 and factor B by these cells. In parallel experiments, IL-1,, over a concentration range of 0.001 to 1.0 ng/ml, had no effect on the production of C2, factor B or factor D (results not shown).
To determine the optimal concentration of IFN-y for C2 production, we performed dose-response studies. U105-MG cells [(1-2) x 107] were incubated without or with increasing amounts of human recombinant IFN-y (125-1000 units/ml) for 48 h. Both C2 protein, quantified by RIMA, and mRNA levels, assessed by Northern blot analysis, were determined. Northern blot analysis (Fig. la) demonstrated that peak levels of C2 mRNA were observed between 250 and 500 units of IFN-y/ml. The blot was stripped and re-probed for cyclophilin mRNA, which is not modulated by IFN-y treatment [29] . The lower portion of Fig. 1(a) shows that essentially equivalent amounts of cyclophilin mRNA were present in each lane. Densitometric scanning of both autoradiograms, to quantitatively compare relative amounts of mRNA in each lane, indicated that C2 mRNA levels were increased between 4-and 6-fold in response to IFN-y concentrations between 250 and 1000 units/ml. Similar increases in C2 protein production were quantified by RIMA (Fig. lb) . There were no statistically significant differences among the amounts of C2 produced in response to 250, 500 or 1000 units of IFN-y/ml. Interestingly, the Northern blot analysis (Fig. la with IFN-y increased the intensity of the larger band by approx. 5-fold over the smaller band, while the intensity of the smaller band increased only slightly. Similar studies were performed to examine IFN-y-induced modulation of factor B expression by U105-MG cells. Fig. 2(a) demonstrates that peak levels of factor B mRNA were observed at between 500 and 1000 units of IFN-y/ml. The stripped and re-probed for cyclophilin mRNA; the resulting autoradiograph is shown in the lower portion of Fig. 2(a) . Densitometric scanning of both autoradiograms to normalize the relative amounts of mRNA between lanes demonstrated that levels of factor B mRNA increased by 4-5-fold in response to IFN-y concentrations between 250 and 1000 units/ml. In contrast, a maximum 3-fold increase in secreted factor B was measured by RIMA (Fig. 2b ). There were essentially no differences in the amounts of factor B secreted when IFN-y concentrations between 250 and 1000 units/ml were used. Factor B and C2 mRNA levels were 2. Fig. 3 . The Northern blot (Fig. 3a) demonstrates an increase in C2 mRNA levels, compared with untreated control cultures, throughout the 120 h time period. Densitometric scanning and normalization for cyclophilin mRNA indicated that IFN-y-induced C2 mRNA levels were about 7-fold higher than those in the untreated controls at 48 h; this decreased to about 3-fold higher than controls throughout the remaining time periods. Essentially no change in C2 mRNA levels was seen in untreated cultures at any time point. C2 protein production increased continuously during the first 72 h. At that time point, IFN-y-stimulated cells had produced 5 times more C2 than control cells. The ratio of C2 protein production in IFN-y-treated versus untreated cells then decreased slightly through the remaining culture period.
The cumulative production of factor B mRNA and protein in response to IFN-y is shown in Fig. 4 declined throughout the remainder of the culture period (Fig.  4a) . Factor B protein levels increased to a maximum of 2.4-fold higher than controls at 48 h, and then declined to 1.6-fold higher than controls at 120 h (Fig. 4b) . Factor D mRNA and protein expression in U105-MG cells In experiments to determine the optimal concentration of IFN-y for factor D production, we found factor D gene expression to be refractory to stimulation by IFN-y (Fig. 5a) . However, as determined by RIMA, U105-MG cells synthesize and secrete significant amounts of factor D (-6-8 ng/ml per 101 cells per day; Fig. 5b ). Kinetic studies also demonstrated no response to 250 units of LFN-y/ml over a 5 day period (results not shown). Western blot analysis of factor D secreted by U 105-MG cells demonstrated that factor D produced by these cells appears as a doublet which may represent slight degradation of the protein or a pro-D and mature D molecule (Fig. 5c4 .
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Biosynthetic labelling studies
Because we detected two C2 transcripts on Northern blot analysis of unstimulated and IFN-y-stimulated U105-MG cells, we performed biosynthetic labelling studies with [35S]methionine to determine whether the cells also synthesized and secreted two C2 proteins. As a control, biosynthetically labelled factor B was also examined. In these experiments, cells were stimulated with 250 units of IFN-y/ml for 48 h prior to labelling, to enhance detection of the proteins, and then treated as described in the Materials and methods section. 35S-labelled C2 and factor B from cell lysates (at time zero and 2 h after chasing with unlabelled methionine), and from culture medium (2 h post-chase) were immunoprecipitated with. polyclonal anti-(human C2) or -(factor B) antibody and subjected to SDS/PAGE. The resulting autoradiographs are shown in Fig. 6 . Fig. 6(a) shows biosynthetically labelled C2 intracellularly at both time zero and 2 h post-chase (lanes 1 and 2) and-in the culture supernatant at 2 h post-chase (lane 3). The apparent molecular mass of C2 synthesized by the U105-Mg cells was slightly higher than that of C2 in serum (-105 kDa versus -100 kDa). A lower-molecularmass band (-70 kDa) was present intracellularly at both time points (lanes 1 and 2), but not in the supernatant. For factor B, two bands of very similar molecular mass were present intracellularly at time zero; however, only a single band was seen at 2 h in the lysate and extracellularly (Fig. 6b) . The apparent molecular mass of factor B produced by U105-MG cells is similar to that of C2 (-105 kDa) and is also slightly higher than that of its serum-derived counterpart. The additional lowermolecular-mass bands in the 30-45 kDa range seen in both panels of Fig. 6 [16] .
Factor D is limited in its cellular expression, with blood monocytes/macrophages [12, 13] , adipocytes [10, 11] and sciatic nerve [11] being the only sites of synthesis currently known. The latter two sites are unique for complement proteins, which are produced predominantly by hepatocytes, monocytes/macrophages, fibroblasts and epithelial and endothelial cells [4, 5, 30] . Stimulation of U105-MG cells by IFN-y had no effect on the expression of factor D mRNA or protein levels (Fig. 5) [14, 15] , suggest that the regulation of factor D gene expression is different from that of most complement components.
Increased C2 and factor B protein and mRNA levels in response to IFN-y have been documented previously in a number of cell types and is tissue-specific [5, 7, 31, 32] . The increases we report here for C2 (4-6 fold) and factor B (4-5 fold) are comparable with those reported for monocytes, monocyte cell lines (U937) and fibroblasts [5, 7, 31, 32] , at both the protein and mRNA levels. Fewer studies have examined the kinetics of C2 and factor B synthesis in response to IFN-y; however, Hamilton and co-workers [33] have reported kinetics ofmonocyte responses similar to those described here. The kinetic studies shown in Figs. 3 and 4 demonstrate that the increased synthesis of C2 and factor B peaks at approx. 48 h. This response is characteristic of most acute-phase proteins [34, 35] . Factor B has been previously shown to be an acute-phase protein, as determined by elevated serum levels in response to infection [21] . Although serum levels of C2 are not elevated in the acute-phase response, increased C2 synthesis by macrophages and fibroblasts in response to LPS and IFN-y [5] suggests that C2 gene expression is up-regulated at tissue sites during the acute-phase response.
The detection of two C2 transcripts (Figs. 1 and 3) is unique for human tissues; however, multiple primary translation products have been identified in primary hepatocyte cultures and HepG2 cells [36] . The larger 2.8 kb C2 transcript is similar in size to that detected previously in human liver [24, 37] . Expression of this transcript was responsive to IFN-y treatment in a dose-and time-dependent fashion (Figs. 1 and 3 ), while the smaller 2.3 kb band responded only weakly to IFN-y treatment. Biosynthetic labelling studies (Fig. 6) Fig. 6(a) . Smaller, cell-associated, forms ofC2 have been reported in HepG2 cells and primary hepatocytes [36] ; thus we may be seeing similar translation products in U105-MG cells. Cell-free translation studies using both total RNA and poly(A)+ mRNA are necessary to address these possibilities. RNAase protection experiments have indicated the presence of two C2 transcripts differing in the size of the 5' untranslated region [8] . The size difference between these alternative C2 mRNAs was estimated to be approx. 150 nucleotides, considerably less than the -500 nucleotide size difference observed in the Northern blots of U105-MG RNA. Similarly, sequence analysis of murine cDNA clones has demonstrated two C2 transcripts in liver arising from alternative splicing mechanisms [38] . However, the size difference (21 nucleotides) is again too small to account for the transcripts we observed. Although multiple transcripts have been reported for murine factor B [39, 40] in kidney and intestine, we observed a single protein band for factor B secreted into the supernatants of U105-MG cells (Fig. 6b) . The doublet seen intracellularly (Fig. 6b, lane 1) probably reflects various levels of glycosylation of factor B. Biosynthetic studies using tunicamycin will help to address this question and to determine if the increased size of the secreted C2 and factor B synthesized by U105-MG cells (Fig. 6 
